Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
Ticker Information
Ticker
KPTICompany Name
KARYOPHARM THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQKARYOPHARM THERAPEUTICS INC - Debt to Equity Ratio Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
KPTI - D/E Historical data
| Date | Debt to Equity Ratio | Shareholders Equity | Total Liabilities |
|---|---|---|---|
| 6/30/2025 | 0 | $ -238.93M | $ 343.81M |
| 3/31/2025 | 0 | $ -205.88M | $ 333.6M |
| 12/31/2024 | 0 | $ -186.02M | $ 350.44M |
| 9/30/2024 | 0 | $ -159.65M | $ 349.12M |
| 6/30/2024 | 0 | $ -132.14M | $ 346.12M |
| 3/31/2024 | 0 | $ -168.96M | $ 373.41M |
| 12/31/2023 | 0 | $ -136.21M | $ 376.64M |
| 9/30/2023 | 0 | $ -100.4M | $ 370.36M |
| 6/30/2023 | 0 | $ -71.25M | $ 369.08M |
| 3/31/2023 | 0 | $ -45.17M | $ 370.97M |
Key Performance Insights, Last 5 Years
- KARYOPHARM THERAPEUTICS INC's latest trailing twelve months (TTM) D/E stands at 3.03.
- Over the past 5 years, KARYOPHARM THERAPEUTICS INC's average D/E has been 4.11.
- The median D/E for KARYOPHARM THERAPEUTICS INC during this period was 4.11
- KARYOPHARM THERAPEUTICS INC reached its highest D/E over the past 5 years at 5.19.
- The lowest D/E recorded by KARYOPHARM THERAPEUTICS INC in the same timeframe 3.03
KARYOPHARM THERAPEUTICS INC's D/E vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
D/E Benchmarks
Similar metrics to Liabilities:
- Debt to Assets Ratio - [Calculation] Debt to Assets measures the ratio between a company’s [Liabilities] and [Assets]. A high ratio might indicate more risk.
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Free Cash Flow to Debt - [Calculation] The Free Cash Flow to Debt ratio allows investors to judge a company’s financial stability. It represents the fraction of debt that could be repaid within one year if all of the free cash flow would be used to repay debt. It is calculated by dividing Free Cash Flow [FCF] by a company’s [Liabilities].
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Debt to Equity Ratio
[Calculation] Debt to Equity (D/E) measures the ratio between a company’s [Liabilities] and [Equity]. A high ratio might indicate more risk.Liabilities / Equity
(=) D/E D/E for KARYOPHARM THERAPEUTICS INC is calculated as follows: Liabilities [ $ 253.82M ] / Equity [ $ 83.77M ]
(=) D/E [ 3.03 ] KPTI - Debt to Equity Ratio, Last 5 years
3.03
Minimum
Sep 30, 2020
5.19
Maximum
Dec 31, 2020
4.11
Average
4.11
Median
D/E Benchmark AnalysisMarket
The chart above depicts the distribution of D/E for companies in the Total Stock Market. The average D/E of the companies is 1.4 with a standard deviation of 1.31.
The following table provides additional summary stats:
D/E in the Market:
| filtered constituents | 3.3K |
|---|---|
| min | 0 |
| max | 6.06 |
| average | 1.4 |
| median | 0.98 |
| std | 1.31 |